OrbiMed

PierianDx Closes up to $47.5 Million of Growth Capital

Retrieved on: 
星期二, 十一月 2, 2021
Technology, Research, Genetics, Software, Biotechnology, Health, Pharmaceutical, Data Management, Science, Technology, Genomics, Inova Health System, NGS, Patient, Genetic variation, Precision medicine, RTI International, CEO, Laboratory, Washington University in St. Louis, Solution, Health, Technology transfer, Pharmaceutical industry, PierianDx, OrbiMed, PIERIANDX, ORBIMED

PierianDx, the global leader in clinical genomics knowledge, announced that it closed on $30 million of new growth capital including equity financing and a term loan facility, which includes access to additional tranches for up to $17.5 million by 2022 and 2023, subject to certain conditions.

Key Points: 
  • PierianDx, the global leader in clinical genomics knowledge, announced that it closed on $30 million of new growth capital including equity financing and a term loan facility, which includes access to additional tranches for up to $17.5 million by 2022 and 2023, subject to certain conditions.
  • The financing was led by healthcare investment firm OrbiMed with existing investors Health Catalyst Capital, Research Triangle Institute, Inova Health Systems, ATW Partners, and SJF Ventures also participating.
  • PierianDx partners directly with providers, laboratories, and medical centers of all sizes to build advanced NGS testing capabilities on site using its assay-agnostic, advanced interpretation technology and enabling services.
  • PierianDx is a partner in precision medicine, enabling clinicians and medical facilities to advance clinical genomics programs and modernize patient care.

ADARx Raises $75 Million to Advance Growing Pipeline

Retrieved on: 
星期三, 九月 8, 2021
Biotechnology, Health, Science, Pharmaceutical, Research, ADARx, SR One, OrbiMed, ADARX, SR ONE, ORBIMED

ADARx Pharmaceuticals, Inc. , a biotechnology company developing RNA targeting therapeutics, today announced the completion of a $75 million Series B financing to advance its drug development pipeline.

Key Points: 
  • ADARx Pharmaceuticals, Inc. , a biotechnology company developing RNA targeting therapeutics, today announced the completion of a $75 million Series B financing to advance its drug development pipeline.
  • The ADARx team is laser-focused on efficiently translating their insights around RNA biology into novel medicines to benefit patients.
  • The proceeds from the Series B financing will be used to advance ADARxs proprietary RNA platform technologies for base editing, inhibition, degradation, and delivery.
  • ADARx has a growing pipeline of RNA targeting therapeutics for treating diseases across a range of therapeutic areas including genetic, cardiometabolic, and central nervous system diseases.

XinThera Closes $50M Series B Financing

Retrieved on: 
星期三, 八月 4, 2021
Biotechnology, Pharmaceutical, Health, Oncology, Finance, Money, Investment, OrbiMed, Investor

XinThera , a company focused on building a small molecule oncology and immunology pipeline, announced today that the company has raised $50M in Series B financing.

Key Points: 
  • XinThera , a company focused on building a small molecule oncology and immunology pipeline, announced today that the company has raised $50M in Series B financing.
  • New investor Orbimed Advisors, LLC joined existing investors Foresite Capital and TTM Capital, bringing the total financing raised to $80M.
  • Stephen Kaldor, Ph.D., co-founder and chairman of XinThera has more than 25 years of experience in creating meaningful medicines and shareholder value.
  • The XinThera team comprises oncology and immunology experts with decades of experience in successfully developing more than seven marketed drugs and has progressed rapidly since its seed financing in February 2021.

Adela Debuts with $60M in Series A Financing and a Breakthrough Approach to Blood-Based Detection of Cancer and Other Diseases

Retrieved on: 
星期三, 六月 23, 2021
OrbiMed, Cancer screening, Cancer

Adelas Series A financing round was led by F-Prime Capital with OrbiMed, Deerfield Management, Decheng Capital, and RA Capital Management participating.

Key Points: 
  • Adelas Series A financing round was led by F-Prime Capital with OrbiMed, Deerfield Management, Decheng Capital, and RA Capital Management participating.
  • This enables us to achieve robust cancer detection as well as tissue-of-origin classification from a single blood sample.
  • Adela plans to develop its technology for use across the entire cancer continuumfor detection, diagnosis, and management of disease.
  • Adela (formerly DNAMx) is focused on the detection of cancer and other high-morbidity, high-mortality conditions through a routine blood test.

Sparrow Pharmaceuticals Secures $50 Million Series A Financing

Retrieved on: 
星期二, 五月 18, 2021
Pharmaceutical, Health, Clinical trials, Steroid, U.S. Venture Partners, Sparrow Pharmaceuticals, OrbiMed, RiverVest, U.S. Venture Partners, SPARROW PHARMACEUTICALS, ORBIMED, RIVERVEST, U.S. VENTURE PARTNERS

b'Sparrow Pharmaceuticals, an emerging clinical-stage biopharmaceutical company developing novel, targeted therapies for disorders of corticosteroid excess, today announced the closing of a $50 million Series A financing.

Key Points: 
  • b'Sparrow Pharmaceuticals, an emerging clinical-stage biopharmaceutical company developing novel, targeted therapies for disorders of corticosteroid excess, today announced the closing of a $50 million Series A financing.
  • OrbiMed led the investment round with participation by RiverVest Venture Partners and U.S. Venture Partners (USVP).
  • This financing will allow the company to accelerate the development of its proprietary oral HSD-1 inhibitor, SPI-62, which targets the source of steroids that cause toxicity in key tissues.
  • To learn more about Sparrow Pharmaceuticals and its pipeline, visit the website at www.SparrowPharma.com .\nSparrow Pharmaceuticals was founded to spare patients the ravages of steroids.

Harbour BioMed Raises $102.8M in Series C Financing to Accelerate Development of Its Innovative Portfolio of Next Generation Biologics

Retrieved on: 
星期四, 七月 9, 2020
Banking, Research, Professional services, Pharmaceutical, Oncology, Infectious diseases, Clinical trials, Science, Biotechnology, Finance, Health, Consulting, Other Science, Life sciences, Articles, Biopharmaceutical, Biotechnology, Pharmaceutical industry, Pharmacy, Harbour BioMed, Hudson Bay Capital, OrbiMed, Country Garden Venture Capital, GTJA Investment Group, Octagon Capital, Sage Partners Fund, Greater Bay Area Fund

Harbour BioMed (HBM) today announced completion of its Series C financing of $102.8 Million to accelerate development of its growing portfolio of next generation biologics targeting cancer, immunologic diseases, and COVID-19.

Key Points: 
  • Harbour BioMed (HBM) today announced completion of its Series C financing of $102.8 Million to accelerate development of its growing portfolio of next generation biologics targeting cancer, immunologic diseases, and COVID-19.
  • We believe the Companys innovative approach, with next generation technologies that target unmet medical needs, presents an exciting growth opportunity."
  • With a patient-centric approach to address unmet medical needs across the world, HBM currently has five products in clinical development.
  • Harbour BioMed is a global, clinical stage biopharmaceutical company developing innovative therapeutics in the fields of immuno-oncology, immunologic diseases, and COVID-19.

Edgewise Therapeutics Closes $50 Million Series B Financing

Retrieved on: 
星期二, 九月 17, 2019
Biotechnology, Pharmaceutical, Health, Infectious diseases, Genetics, Other Health, Branches of biology, Muscular dystrophy, Becker muscular dystrophy, Edgewise, Dystrophin, Muscular Dystrophy, Edgewise Therapeutics, Novo Holdings A/S, U.S. Venture Partner, OrbiMed

Edgewise Therapeutics, a preclinical company developing small molecule therapies for musculoskeletal diseases, has announced the closing of a $50 million Series B financing round.

Key Points: 
  • Edgewise Therapeutics, a preclinical company developing small molecule therapies for musculoskeletal diseases, has announced the closing of a $50 million Series B financing round.
  • The financing will support the advancement of Edgewise Therapeutics lead product candidate into clinical development for Duchenne and Becker Muscular Dystrophy (DMD and BMD) as well as expansion of the companys pipeline.
  • We are excited to have the support of a group of leading life science investors in our Series B financing as we continue to execute against our vision of building a company that will transform the lives of patients living with severe musculoskeletal diseases, said Kevin Koch, Ph.D., President and Chief Executive Officer, Edgewise Therapeutics.
  • We have great respect for the team at Edgewise Therapeutics and CureDuchenne Ventures is pleased to participate in this Series B financing to help speed the progression of the companys innovative approach into clinical testing.